RLYB News and Press, Rallybio Corporation From 11/11/22

Rallybio Corporation ( NASDAQ: RLYB ) has priced an underwritten public offering of 5M shares of its common stock at a price to the public of $6.00/share and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 3,333,388 shares o...

Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the pricing of an underwritten public offering of 5,000,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to pur...

Rallybio ( NASDAQ: RLYB ) is down -8.5% following the commencement of a proposed public offering of $75M of common stock or pre-funded warrants. The company will offer all of the shares and pre-funded warrants and expects to grant underwriters a 30-day option to purcha...

Rallybio Corporation (“Rallybio”) (Nasdaq: RLYB) today announced the commencement of a proposed public offering of $75 million of its shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock). All...

Rallybio ( NASDAQ: RLYB ) reported positive phase 1 top-line results for its complement-mediated diseases candidate RLYB116. In the study, a single, 1mL subcutaneous injection of 100 mg of RLYB116 led to a reduction in free C5 more than 99% within 24 hours of dosing. ...

Rallybio press release ( NASDAQ: RLYB ): Q3 GAAP EPS of -$0.60 misses by $0.06 . Cash and cash equivalents of $132.420. For further details see: Rallybio GAAP EPS of -$0.60 misses by $0.06

-- Preliminary results from Phase 1b study of RLYB212 showed rapid and complete elimination of transfused platelets in all subjects to date; Proof-of-concept data expected in 1Q 2023 -- -- Positive 100 mg results of Phase 1 study of RLYB116 showed reduction of >99% in free ...

-- 100 mg Results Demonstrated a Reduction of >99% in Free C5 with the Potential for Weekly or Less Frequent Self-Administered Dosing -- -- RLYB116 Administered as a Single 100 mg dose was Generally Well-Tolerated -- -- Phase 1 Multiple Ascending Dose Study Expected to ...

-- Preliminary data from the ongoing Phase 1b study shows RLYB212 rapidly and completely eliminates transfused HPA-1a positive platelets -- -- Proof-of-Concept Data Expected in 1Q 2023 -- Rallybio Corporation (Nasdaq: RLYB) today announced positive preliminary resu...

Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...